COLUMBUS, OH - Feb 23, 2015 - GenomeNext, LLC, a leader in genomic data management and integrated analysis, announced today an agreement with Nationwide Children’s Hospital under which Nationwide  Children’s will integrate GenomeNext’s genomic sequencing analysis platform for both clinical laboratory services and clinical research initiatives.

Despite tremendous developments in advanced sequencing technologies over the past several years, addressing the computational bottlenecks at the speeds and reproducibility required to translate genomic sequencing into clinical practice remains a challenge.  The GenomeNext platform effectively addresses these hurdles by delivering genomic sequence analysis at the speed and with the reproducibility required for clinical application.

The integration of the GenomeNext pipeline provides Nationwide Children’s with automated informatics on an enterprise cloud platform to power downstream sequencing analysis in a secure and compliant environment.  The infrastructure and compute required for complex genomic analysis incorporates proprietary methodologies that yield deterministic results essential for making confident, informed decisions.  

GenomeNext’s combination of speed and determinism coupled with its fully automated SaaS solution continues to enable its customers to effectively analyze and access their data on a simplified, easy-to-use platform.  “We are excited to work with Nationwide Children’s to contribute to its dedicated efforts to create the future of pediatric health care.  Nationwide Children’s commitment to realizing the promise of precision medicine to shape the future health and opportunity of all children is extraordinary and we are pleased our Platform can play an integral role,” said James Hirmas, CEO of GenomeNext.  “Nationwide Children’s adoption of our Platform further validates the utility of the GenomeNext solution in clinical practice.”

“GenomeNext has proven its capabilities in the research arena. Now we look forward to the expanded clinical genomics services we will be able to provide our patients and their families as we integrate this technology into our current state-of-the-art clinical laboratories,” states Sue Hammond, MD, chief, Department of Pathology and Laboratory Medicine at Nationwide Children’s Hospital.

“While genome sequencing is quickly becoming a commodity, it is the ability to creatively and accurately analyze the terabytes of data that come from genome sequencing that is so very important in pediatric medicine today,” says John Barnard, MD, president, The Research Institute at Nationwide Children’s Hospital. “With the right resources and being at the forefront of available technologies, we are uniquely positioned to affect positive change in pediatric health with best outcomes for every child in mind.”

The SaaS is offered through the company’s website,http://www.genomenext.com/.  Alternative configurations are considered upon request.

Genomics Simplified™

About GenomeNext - GenomeNext is a genomic informatics company dedicated to accelerating the promise and capability of predictive medicine and scientific discovery.  We commercialize genomic analysis tools and integrated systems for the evaluation of genetic variation and function.  Our advanced informatics and data management solutions are designed to simplify, expedite and enhance genetic analysis workflows.  Our solutions provide the market with genomic data and analysis at an unprecedented combination of performance, quality, cost and scale without requiring the investment in high-performance computing resources and specialized personnel. Our proprietary platforms address a broad range of highly interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics.  Our customers include leading genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies.

© 2015 GenomeNext, LLC.  GenomeNext is a trademark of GenomeNext, LLC.  All rights reserved.